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Background
The association between pioglitazone use in patients
with type 2 diabetes and thyroid cancer risk has not
been investigated.
Materials and methods
The reimbursement data of all diabetic patients treated
with oral anti-diabetic agents or insulin within the period
from 1996 to 2009 were retrieved from the Taiwan’s
National Health Insurance. An entry date was set at
1 January 2006 and the incidence of thyroid cancer was
followed up until the end of 2009 in 1097215 patients with
type 2 diabetes. Incidences for ever-users, never-users and
subgroups of dose-response exposure to pioglitazone (i.e.
tertile cutoffs of cumulative duration and cumulative dose)
were calculated. Cox regression was used to estimate the
hazard ratios after adjustment for age, sex, diabetes
duration, comorbidities (hypertension, obstructive pul-
monary disease, stroke, ischemic heart disease, peripheral
arterial disease, eye disease, obesity, dyslipidemia, previous
thyroid benign disease, and other cancer), medications
(statin, fibrate, angiotensin-converting enzyme inhibitor
and/or angiotensin receptor blocker, calcium channel
blocker, sulfonylurea, metformin, insulin acarbose, rosigli-
tazone, aspirin, ticlopidine, clopidogrel, dipyridamole and
non-steroidal anti-inflammatory drugs) and potential
detection examinations (thyroid sonography, thyroid
aspiration, and/or thyroid function test).
Results
There were 58378 ever-users and 1038837 never-users,
with respective number of incident thyroid cancer:
48 (0.08%) and 921 (0.09%). Neither the overall hazard
ratio nor any of the dose-response parameters showed
significant association.
Conclusions
Pioglitazone use has a null association with thyroid
cancer risk.
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